Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients

Gastric Cancer

Volumn 16, Issue 3, 2013, Pages 324-328

  Fuse, Nozomu ^a   Nagahisa Oku, Emiko ^a   Doi, Toshihiko ^a   Sasaki, Takahide ^a   Nomura, Shogo ^a   Kojima, Takashi ^a   Yano, Tomonori ^a   Tahara, Makoto ^a   Yoshino, Takayuki ^a   Ohtsu, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Gastric cancer; RECIST; Target lesion

Indexed keywords

CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER CLASSIFICATION; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MCNEMAR TEST; MULTIPLE CYCLE TREATMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PERITONEUM METASTASIS; PRIORITY JOURNAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR 1.0; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR 1.1; RETROSPECTIVE STUDY; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

EID: 84880772753     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-012-0187-9     Document Type: Article

References (12)

1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
2. Bogaerts J, Ford R, Sargent D, Schwartz LH, Rubinstein L, Lacombe D, et al. Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer. 2009;45:248-60.
3. Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24:2188-96.
4. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003;21:54-9.
5. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063-9.
6. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-21.
7. Schwartz LH, Bogaerts J, Ford R, Shankar L, Therasse P, Gwyther S, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer. 2009;45:261-7.
8. Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer. 2011;14:72-80.
9. Fujii M, Kim YH, Satoh T, Hosaka H, Kim T, Tsuji A, et al. Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): the START trial update. ASCO Meeting Abstracts. 2011;29:4016.
10. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28:1547-53.
11. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29:3968-76.
12. Fuse N, Fukuda H, Yamada Y, Sawaki A, Koizumi W, Suzuki Y, et al. Updated results of randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912). ASCO Meeting Abstracts. 2009;27:4514.